Dyslipidemia is independently associated with AF incidence (Guan et al., 2020), and lipid metabolism related proteins serve as a potential AF biomarker (such as LDL, VLDL, HDL, and FABP3) (Golaszewska et al., 2019). This evidence concerns the gene FABP3 and metabolic syndrome.